CLAIMS

1. A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof:

$$R^1\text{-}X\text{-}R^2$$

(I)

wherein

R^1 is phenyl or 6-membered heteroaryl, optionally substituted with one or more substituents selected from halogen, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, C_{1-4}alkoxy-C_{1-4}alkyl, hydroxy-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, amino-C_{1-4}-alkyl, C_{1-4}-alkylamino-C_{1-4}-alkyl, di(C_{1-4}-alkyl)amino-C_{1-4}-alkyl, $-NR^{4A}R^{4B}$, $-NR^6C(O)OR^5$, $-NR^6C(O)R^5$, $-NR^6C(O)NR^{4A}R^{4B}$, $-C(O)NR^{4A}R^{4B}$, $-C(O)R^5$, $-C(O)OR^5$, and $-NR^6S(O)_2R^5$;

R^2 is -B-Q-$[R^3]_n$ or -B-R^3;

wherein n = 1, 2, 3, or 4

B is a bond, O, NR^4, -C(O)- or C_{1-3}-alkylene;

Q is saturated or partially unsaturated monocyclic 3-7 membered heterocyclic or C_{3-7}-cycloalkyl ring;

when R^2 is -B-Q-$[R^3]_n$, R^3 is independently selected from: 3-7 membered heterocyclyl-, 3-7 membered heterocyclyl-C_{1-4}-alkyl-, (3-7 membered heterocyclyl-C_{1-4}-alkyl)-amino-C_{1-4}-alkyl-, amino-C_{1-4}-alkoxy-C_{1-4}-alkyl-, (amino-C_{1-4}-alkyl)-amino-C_{1-4}-alkyl-, $-C_{1-4}$-alkyl-$NR^6C(O)OR^5$, $-C_{1-4}$-alkyl-$NR^6C(O)NR^{4A}R^{4B}$, $-C_{1-4}$-alkyl-$C(O)NR^{4A}R^{4B}$, (3-7 membered heterocyclyl-C_{1-4}-alkyl)-C(O)-, $-C_{1-4}$-alkyl-$C(O)OR^5$, $-OC(O)R^5$, or

$-C(O)NR^{9A}R^{9B}$ wherein R^{9A} and R^{9B} together with the nitrogen to which they are attached form a 3-7 membered cyclic amino group substituted with one or more substituents selected from: C_{1-4}-alkyl, C_{1-4}alkoxy-C_{1-4}alkyl-, C_{3-7}-cycloalkyl, or

-C(O)NR^6R^{10B} wherein R^{10B} is 3-7 membered heterocyclyl- or 3-7 membered heterocyclyl-C_{1-4}-alkyl-, or -C_{1-4}-alkyl-$NR^6C(O)R^5$; or

when R^2 is -B-R^3, R^3 is –NR^6R^{11B}, wherein R^{11B} is 3-7 membered heterocyclyl-C_{1-4}-alkyl-;

R^{4A}, R^{4B} and R^5 are each independently selected from hydrogen, C_{1-4}-alkyl-, 3-7 membered heterocyclyl-C_{1-4}-alkyl-, amino-C_{1-4}-alkyl-, 3-7 membered heterocyclyl-, -C_{1-4}-alkyl-$NR^6C(O)OR^5$, C_{3-7}-cycloalkyl,

or R^{4A} and R^{4B} together with the nitrogen to which they are attached form a 3-7 membered cyclic amino group, optionally substituted by one or more substituents selected from: C_{1-4}-alkyl, -$NR^{4A}R^{4B}$;

unless otherwise specified, 3-7 membered heterocyclyl, or the heterocyclyl part of the 3-7 membered heterocyclyl-C_{1-4}-alkyl-, (3-7 membered heterocyclyl-C_{1-4}-alkyl)-amino-C_{1-4}-alkyl-, or (3-7 membered heterocyclyl-C_{1-4}-alkyl)-C(O)- group is optionally substituted with one or more substituents selected from C_{1-4}-alkyl-, -$C(O)OR^5$, -$C(O)R^5$, -$C(O)NR^{4A}R^{4B}$, -$NR^{4A}R^{4B}$, -C_{1-4}-alkyl-$C(O)NR^{4A}R^{4B}$, or C_{1-4}alkoxy-C_{1-4}alkyl; and

where present, the diradical -C_{1-4}-alkyl- group directly attached to Q is optionally substituted with one or more groups independently selected from halogen, amino, methoxy, hydroxyl;

R^4 and R^6 are each independently selected from hydrogen or C_{1-4}-alkyl; and

X is selected from the radicals of formulae (1-16) wherein the bond marked * is attached to R^1- and the bond marked ** is attached to -R^2:



wherein Y is selected from hydrogen, hydroxyl, amino, -NHR^6, -OCH$_3$;

Z is selected from hydrogen, fluorine, hydroxyl, C$_{1-4}$-alkoxy, halo-C$_{1-4}$-alkyl, CONH$_2$, cyano, SO$_2$NH$_2$, amino, -NHR^6;

W is selected from H, C$_{1-4}$-alkyl, halo-C$_{1-4}$-alkyl,

PROVIDED THAT when R^2 is -B-Q-[R^3]$_n$, and R^3 is 3-7 membered heterocyclyl-, the heterocyclic ring atom directly bonded to Q is not nitrogen, and

PROVIDED THAT the compound of formula (I) is not:



, nor



.

2. A compound according to claim 1 wherein X is selected from the radicals of formulae 1 or 3.

3. A compound according to claim 1 or 2 wherein R^1 is phenyl optionally substituted with one or more substituents as defined in claim 1.

4. A compound according to any one of claims 1 to 3 wherein R^1 is optionally substituted by halogen, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl.

5. A compound according to any one of claims 1 to 4 wherein B is a bond.

6. A compound as claimed in any of claims 1 to 5 wherein R^2 is -B-Q-$[R^3]_n$, and Q is a saturated or partially unsaturated 5 or 6 membered heterocyclic or cycloalkyl ring.

7. A compound as claimed in claim ~~7~~ 6 wherein Q is selected from tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, cyclohexyl, or any of the foregoing rings comprising a bridge formed by an ethylene or propylene radical.

8. A compound according to any one of claims 1 to 6 wherein R^2 is:

wherein

T is N or CH

R^6 is hydrogen or C_{1-4}-alkyl

R^{10B} is 3-7 membered heterocyclyl-, or 3-7 membered heterocyclyl-C_{1-4}-alkyl-, either of which heterocyclic rings is optionally substituted by one or more substituents selected from C_{1-4}-alkyl- and C_{1-4}alkoxy-C_{1-4}alkyl.

9. A compound according to claim 8 wherein R^2 is:



wherein:

T is N or CH;

P is a direct bond or a diradical selected from methylene, ethylene, or propylene;

R^6 is hydrogen or C_{1-4}-alkyl;

R^{12} is selected from hydrogen, C_{1-4}-alkyl- and C_{1-4}alkoxy-C_{1-4}alkyl-.

10. A compound according to claim 8 wherein R^2 is:



wherein

T is N or CH;

P is a diradical selected from methylene, ethylene, or propylene;

R^6 is hydrogen or C_{1-4}-alkyl;

R^{12} is selected from hydrogen, C_{1-4}-alkyl, and C_{1-4}alkoxy-C_{1-4}alkyl-.

11. A compound according to any one of claims 1 to 6 wherein R^2 is:



wherein

R^3 is $-C_{1-4}$-alkylC(O)$NR^{4A}R^{4B}$ wherein

R^{4A} and R^{4B} are each independently selected from hydrogen, C_{1-4}-alkyl-, and amino-C_{1-4}-alkyl-, or

R^{4A} and R^{4B} together with the nitrogen to which they are attached form a 3-7 membered cyclic amino group, optionally substituted by one or more substituents selected from: C_{1-4}-alkyl, or -$NR^{4A}R^{4B}$; ~~or~~.

12. A compound as claimed in claim 1 which is: 4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-1-(pyrrolidin-3-yl)piperidine;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-1-(piperidin-4-yl)piperidine;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-1-(piperidin-4-ylmethyl) piperidine;
1-{4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-2-(piperidin-4-yl)ethan-1-one;
1-({4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-4-methylpiperazine;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-(piperidin-4-ylmethyl)piperidine-1-carboxamide;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-(piperidin-4-yl)piperidine-1-carboxamide;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-(1-methylpiperidin-4-yl)piperidine-1-carboxamide;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[1-(propan-2-yl)piperidin-4-yl]piperidine-1-carboxamide;
N-(1-Acetylpiperidin-4-yl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[(1-methylpiperidin-4-yl)methyl]piperidine-1-carboxamide;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[(1-ethylpiperidin-4-yl)methyl]piperidine-1-carboxamide;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-methyl-N-[(1-methylpiperidin-4-yl)methyl]piperidine-1-carboxamide;
N-{[1-(Carbamoylmethyl)piperidin-4-yl]methyl}-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-methyl-N-{[1-(propan-2-yl)piperidin-4-yl]methyl}piperidine-1-carboxamide;
1-({4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-4-cyclopropylpiperazine;

1-({4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-4-(propan-2-yl)piperazine;
1-({4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-4-(2-methoxyethyl) piperazine;
(3S)-1-({4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-3-(propan-2-yl)piperazine;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-(morpholin-2-ylmethyl)piperidine-1-carboxamide;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[(1,4-dimethyl piperazin-2-yl)methyl]piperidine-1-carboxamide;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[2-(morpholin-4-yl)ethyl]piperidine-1-carboxamide;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[2-(piperazin-1-yl)ethyl]piperidine-1-carboxamide;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[2-(1-methylpiperidin-4-yl)ethyl]piperidine-1-carboxamide;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[2-(4-methylpiperazin-1-yl)ethyl]piperidine-1-carboxamide;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(morpholin-4-yl)propyl]piperidine-1-carboxamide;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-{[1-(propan-2-yl)piperidin-4-yl]methyl}piperidine-1-carboxamide;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-{[1-(2-methoxyethyl)piperidin-4-yl]methyl}piperidine-1-carboxamide;
N-[3-({4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonylamino)propyl]acetamide;
Propan-2-yl N-({4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)carbamate;
3-Cyclopropyl-1-({4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)urea;
2-({4-[1-(4-Methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methoxy)ethan-1-amine;
(2-Aminoethyl)({4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)amine;
4-[1-(4-Methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]-2-(morpholin-4-

ylmethyl)morpholine;
4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]-2-[(4-methylpiperazin-1-yl)methyl]morpholine;
4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]-2-(piperazin-1-ylmethyl) morpholine;
3-Aminopropyl 4-({4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)piperazine-1-carboxylate;
N-(3-Aminopropyl)-4-({4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl] morpholin-2-yl}methyl)piperazine-1-carboxamide;
4-({4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)-N-ethylpiperazine-1-carboxamide;
Methyl 2-{4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}acetate;
4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]-3-(morpholin-4-ylmethyl)morpholine;
4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]-3-[2-(4-methylpiperazin-1-yl)ethyl]morpholine;
1-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]-N-[(1-methylpiperidin-4-yl)methyl]piperidine-2-carboxamide;
1-(4-Chlorophenyl)-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazolo[3,4-c]pyridin-3-amine;
1-(4-Chlorophenyl)-N-[2-(piperazin-1-yl)ethyl]-1H-pyrazolo[3,4-c]pyridin-3-amine;
1-(4-Chlorophenyl)-N-[2-(4-methylpiperazin-1-yl)ethyl]-1H-pyrazolo[3,4-c]pyridin-3-amine;
1-[1-(4-Chlorophenyl)-1H-pyrazolo [3,4-c]pyridin-3-yl]-N-(piperidin-4-ylmethyl)piperidine-4-carboxamide;
4-({1-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl}methyl) morpholine;
1-({1-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl}methyl)piperazine;
({1-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl}methyl)(piperidin-4-ylmethyl)amine;
4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]-N-[(1-methylpiperidin-4-yl)methyl]piperazine-1-carboxamide;
2-{4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}acetic acid;
N-(2-Aminoethyl)-2-{4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl] morpholin-

3-yl}acetamide;
2-{4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}-1-(4-methylpiperazin-1-yl)ethan-1-one;
2-{4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}-1-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]ethan-1-one;
2-{4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}-N-(1-methylpiperidin-4-yl)acetamide;
2-{4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}-N-[(1-methylpiperidin-4-yl)methyl]acetamide;
({4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)urea;
1-({4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)-3-methylurea; and
1-(2-{[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]amino}ethyl)imidazolidin-2-one

~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-(piperidin-4-ylmethyl)piperidine-1-carboxamide~~
~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-(1-methylpiperidin-4-yl)piperidine-1-carboxamide~~
~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[(1-methylpiperidin-4-yl)methyl]piperidine-1-carboxamide~~
~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[(1-ethylpiperidin-4-yl)methyl]piperidine-1-carboxamide~~
~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-methyl-N-[(1-methylpiperidin-4-yl)methyl]piperidine-1-carboxamide~~
~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[2-(piperazin-1-yl)ethyl]piperidine-1-carboxamide~~
~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[2-(1-methylpiperidin-4-yl)ethyl]piperidine-1-carboxamide~~
~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(morpholin-4-yl)propyl]piperidine-1-carboxamide~~
~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-{[1-(propan-2-yl)piperidin-4-yl]methyl}piperidine-1-carboxamide~~
~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-{[1-(2-methoxyethyl)piperidin-4-yl]methyl}piperidine-1-carboxamide~~

~~4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]-N-[(1-methylpiperidin-4-yl)methyl]piperazine-1-carboxamide~~

~~N-(2-Aminoethyl)-2-{4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl] morpholin-3-yl}acetamide~~

~~2-{4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}-1-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]ethan-1-one~~

or a pharmaceutically acceptable salt, or N-oxide thereof.

13. A pharmaceutical composition comprising a compound as claimed in any of the preceding claims or 1-[1-(4-Methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl acetate, together with one or more pharmaceutically acceptable carriers and/or excipients.

~~14. A compound as claimed in any of claims 1 to 12 or for use in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth.~~

~~15~~14. The use of a compound as claimed in any of claims 1 to 12 or 1-[1-(4-Methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl acetate in the manufacture of a ~~composition~~ medicament for treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth.

~~16. A method for the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth, which comprises administering to a subject suffering such disease an effective amount of a compound of formula (I) as claimed in any of claims 1 to 12.~~

~~17~~15. ~~A compound as claimed in any one of claims 1 to 12, or~~The use as claimed in claim ~~15~~14 ~~, or the method as claimed in claim 16~~ wherein the inflammation or inflammatory disease or immune or autoimmune disorder is arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis and psoriatic arthritis), synovitis, vasculitis, a condition associated with inflammation of the bowel (including Crohn's disease, ulcerative colitis, inflammatory bowel disease and irritable bowel syndrome), atherosclerosis, multiple sclerosis, Alzheimer's disease,

vascular dementia, a pulmonary inflammatory disease (including asthma, chronic obstructive pulmonary disease and acute respiratory distress syndrome), a fibrotic disease (including cystic fibrosis, idiopathic pulmonary fibrosis, cardiac fibrosis and systemic sclerosis (scleroderma)), an inflammatory disease of the skin (including contact dermatitis, atopic dermatitis and psoriasis), systemic inflammatory response syndrome, sepsis, an inflammatory and/or autoimmune condition of the liver (including autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, sclerosing cholangitis, and autoimmune cholangitis), diabetes (type I or II) and/or the complications thereof, chronic heart failure, congestive heart failure, an ischemic disease (including stroke and ischemia-reperfusion injury) or myocardial infarction and/or the complications thereof.

~~18~~16. ~~A compound as claimed in any one of claims 1 to 12, or~~The use as claimed in claim ~~15~~14 ~~, or method as claimed in claim 16,~~ wherein the inflammatory disease is rheumatoid arthritis, chronic obstructive pulmonary disease or atopic dermatitis.

~~19~~17. ~~A compound as claimed in any one of claims 1 to 12, or~~The use as claimed in claim ~~15~~14 ~~, or the method as claimed in claim 16~~ for inhibition of tumour growth.